secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001558370-23-012816
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics Q2 cash $58M; uproleselan Phase 3 topline by Q2 2024; GMI-1687 Phase 1a in Q3
--------------------------------------------------------------------------------

- Cash $58.0M at June 30, 2023, up from $47.9M at Dec 31, 2022; R&D spend $4.1M, down 49% YoY.
- Pivotal Phase 3 uproleselan R/R AML topline results expected by end of Q2 2024 after time-based analysis amendment.
- FDA agreed to initial Pediatric Study Plan; NCI will sponsor Phase 1/2 uproleselan study in pediatric AML.
- First pediatric patient dosed in investigator-initiated Phase 1/2 study of uproleselan with pre-transplant conditioning.
- GMI-1687 (E-selectin antagonist) Phase 1a study in healthy volunteers to initiate in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/0001558370-23-012816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/glyc-20230802x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer